Prophylactic antibacterials backed by CARB-X: Data Byte

Since its 2016 launch, CARB-X has awarded $249.1 million across 67 therapeutics, vaccines and rapid diagnostic programs against the most serious drug-resistant bacteria identified by the WHO and CDC.

Nine of those awards went to companies developing prophylactics, the most recent awardee being Lumen Bioscience Inc. Lumen launched its CARB-X-funded project last week to develop an oral mAb cocktail to prevent serious diarrheal diseases. The company’s spirulina platform could improve access to all biologics by lowering the costs, IV delivery requirements and safety hurdles that have historically restricted their use to cancer and autoimmune therapies in the West. ...